Gonorrhoea is now said to be the second most common notifiable disease in the world, only measles being more prevalent. As stated in a recent leading article: 'With a mass measles vaccination just around the corner, it is a safe bet that gonorrhoea will take first place before very long ' (Lancet, 1970) . Nonspecific urethritis is even more common. In 1970 there were 36,996 cases of gonorrhoea in men and 16,556 in women in England, while in the same year there were 46,075 cases of nonspecific urethritis in men (Annual Report of the Chief Medical Officer, 1970) .
Both gonococcal and nonspecific urethritis present problems in diagnosis and treatment, the most clamant possibly being in the latter category. A recent article (Phillips, Rimmer, Ridley, Lynn, and Warren, 1970) showed the relative resistance to penicillin, long the standard treatment in gonorrhoea, was found in 37 per cent. of gonococci isolated at St Thomas' Hospital in London, and although there is an evident variation in the sensitivity of strains in different parts of the country there is little doubt that this finding will become commonplace. Increasing the dose of penicillin is a self-limiting procedure, so there is need for an agent which will prove more effective against this common condition.
A further problem in the treatment of both gonococcal and nonspecific urethritis is that of administration of drugs and follow-up. It is a common experience to find that patients given a course of tablets may stop taking them as soon as the symptoms have been relieved, and there is little doubt that this practice has contributed to the persistence of partially resistant strains in the community. Patients fail to return to clinics for further treatment and investigation, so that the assessment of any new treatment for these conditions is rendered more difficult.
It was with these problems in mind that we undertook a trial of Vibramycin (doxycycline HCI) in the treatment of acute urethritis in male patients. This antibiotic had previously been shown to be effective in a single oral dose in the treatment of gonorrhoea Received for publication September 4, 1971 in men (Sylvestre and Gallai, 1968) and Domescik, McLone, Scotti, and Mackey, 1969 Evidently, Vibramycin, which is effective in the treatment of that condition (see below), does not always exert a prophylactic action. These eight patients together with the five defaulters were excluded from the trial, leaving 94 who were followed.
Twelve patients had or developed gonococcal urethritis after treatment. As before, diagnosis was confirmed by culture. Of these patients, six (6-4 per cent.) were probably re-infected. This assessment was based on (1) admitted re-exposure to infection and (2) altered antibiogram of the infecting organism (Table IV) .
In six (6,4 per cent.) the infection did not respond to Vibramycin, and, whether or not alcohol had been consumed, these were regarded as treatment failures.
The full period of surveillance was completed by 49 patients (45 8 per cent.), and thev were clinically cured at that time.
NONSPECIFIC URETHRITIS
Fourteen of the 122 patients followed showed evidence of post-treatment urethritis during the period of surveillance (Table III) The failure rate in NSU in this series was 6,7 per cent. Vibramycin failed to prevent the development of NSU in eight patients (7 5 per cent.) in whom it was effective in curing concurrent gonorrhoea. The results of treatment compare favourably with the failure rates observed using pyrrolinomethyl tetracycline 350 mg. intra-muscularly on 2 consecutive days (Schofield and Masterton, 1969) , and the results using oral tetraclycline given for either a 3-or 5-day course (Table VII) .
Single dosage oral treatment for nonspecific urethritis is bound to be controversial, and we therefore deferred judgement until we could complete a long-term assessment at the end of a 12-month period of surveillance. It is well known that nonspecific urethritis, when treated with the tetracycline group, has a disappointingly high recurrence rate. In fact, fewer cases of long-term recurrences presented after single dosage Vibramycin treatment than after other more prolonged tetracycline regimes (Table VIII) . For purposes of comparison, we made no attempt to differentiate between re-infection and relapse and nearly half of these recurrent infections appeared within the first 2 months of surveillance ( Table IX) .
The great advantage of Vibramycin is its effectiveness against both gonorrhoea and NSU in a single oral dose. Immediate oral treatment is clearly of value in those isolated centres which can be medically supervised only occasionally. Since Vibramycin is equally effective against both NSU and gonorrhoea, immediate diagnosis is no longer so essential. For Vibramycin is the obvious choice for the 'needleshy' patient, and it should be of value on merchant vessels when urethritis is treated in the absence of a doctor, slides having been previously taken in accordance with the 'Ship Captain's Medical Guide ' (1967) . The incidence of side-effects is low: in this series the few cases of nausea and vomiting were easily controlled by the administration of a glass of milk together with the single dose of Vibramycin.
Current practice in dealing with strains of N. gonorrhoeae increasingly resistant to penicillin is to increase the dose of penicillin, but this is a selflimiting procedure. Alternative antibiotic treatment is also being given, and Vibramycin has been shown in this series to be an effective agent in the treatment of both gonorrhoea and nonspecific urethritis, penicillin being ineffective against the latter.
The main advantages of Vibramycin in this field are therefore its overall effectiveness against both gonorrhoea and nonspecific urethritis, and the fact that a treatment curative for the majority of cases can be administered as a single oral dose in the presence of the clinician or nurse, thus ensuring that the whole of the treatment is effectively taken without having recourse to injection. Summary 107 male patients suffering from acute gonococcal urethritis and 134 male patients suffering from nonspecific urethritis, were treated with a single oral dose of 300 mg. Vibramycin. Our low failure rate was 6-4 per cent. in 94 cases of uncomplicated gonorrhoea which were followed, and 6-7 per cent. in 119 cases of nonspecific urethritis. These results compare well with those obtained at the same clinics using crystalline penicillin or ampicillin in gonococcal infections and oxytetracycline in nonspecific urethritis. Nausea 
